CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 21, 2018– Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY),
Orphazyme Announces Enrollment of First Patient in Phase III Clinical Trial of Arimoclomol for ALS
Copenhagen, August 10, 2018 – Orphazyme A/S, a biopharmaceutical company